Related Experiment Video
Updated: Dec 6, 2025

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
Closure Device-Related Thrombosis After Anticoagulation With Dabigatran in Patients Undergoing Percutaneous Left
Xiaoye Li1, Qinchun Jin2, Xiaochun Zhang2
1Department of Pharmacy, Zhongshan Hospital, Fudan University, Shanghai, China.
Insights
Left atrial appendage closure (LAAC) prevents stroke in atrial fibrillation (AF) patients. Rare device-related thrombosis (DRT) occurred with dabigatran but resolved after switching to rivaroxaban or warfarin.
Area of Science:
- Cardiology
- Medical Devices
- Thrombosis
Background:
- Percutaneous left atrial appendage closure (LAAC) is a stroke prevention strategy for atrial fibrillation (AF) patients intolerant to long-term anticoagulation.
- LAAC devices aim to reduce thromboembolic events in high-risk AF populations.
Observation:
- Four rare cases of device-related thrombosis (DRT) were observed after successful LAAC procedures.
- Patients received dabigatran anticoagulation post-procedure, and DRT was diagnosed via transesophageal echocardiogram (TEE) during follow-up.
Findings:
- Thrombosis formed on the LAAC occluder device despite dabigatran therapy.
- Switching anticoagulation from dabigatran to rivaroxaban or warfarin led to thrombosis regression within one month.
Implications:
- These findings highlight a potential complication of LAAC with specific anticoagulants.
- Alternative anticoagulation strategies may be necessary for managing DRT after LAAC.
- Further research is warranted to optimize anticoagulation protocols post-LAAC to prevent DRT.
Abstract:
Percutaneous left atrial appendage closure (LAAC) is an effective and safe operation strategy for stroke prevention in patients who are diagnosed with atrial fibrillation (AF) but cannot tolerate long term anticoagulation medication. We presented four rare cases of thrombosis formation on the occluder device. After the LAAC operation was successfully performed on patients, they followed a course of anticoagulation with dabigatran (110 mg b.i.d.), and device-related thrombosis (DRT) occurred as indicated by a transesophageal echocardiogram (TEE) during the follow-up period. Regressions were achieved after replacing dabigatran with rivaroxaban or warfarin for more than 1 month. No thrombosis or bleeding-related complications occurred in subsequent follow-ups.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

